Montreal, Canada

Engene, Inc.

USPTO Granted Patents = 10

% Expired Patents = 20.0


Trademarks = 1

Forward Citations = 36

Loading Chart...
Loading Chart...

10 inventors (with patents filed for the assignee):

goldMedal Anthony Cheung (9 out of 14 patents)

silverMedal Eric Hsu (8 out of 13 patents)

bronzeMedal Jun Gao (6 out of 27 patents)

4.  Carlos Fleet (3 out of 3 patents)

5.  Yu-Kyoung Oh (1 out of 7 patents)

6.  Sang Myoung Noh (1 out of 4 patents)

7.  Myung-Ok Park (1 out of 5 patents)

8.  Sung Sik Bang (1 out of 1 patent)

9.  Timothy Kieffer (1 out of 1 patent)

10.  Myung Suk Kim (1 out of 7 patents)

11.  Timothy J Kieffer (1 patent)

12.  Anthony T Cheung (0 patent)

13.  Eric C Hsu (0 patent)


10 patents:

Company Overview
Engene, Inc. is a Montreal-based company specializing in advanced technologies for the life sciences sector. The organization focuses on developing innovative solutions that enhance research and development processes, particularly in drug discovery and biotechnology. Engene's expertise spans various domains, including bioinformatics, molecular biology, and data analytics, enabling it to support pharmaceutical and biotech companies in accelerating their product development timelines and improving outcomes in healthcare.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Engene, Inc. USPTO Patent Assignee Logo
10 Patents

#108 in Montreal

#1,525 in Canada

#56,092 in the World

Montreal, CA
Montreal, Canada
Forward Citations = 36

10 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Engene, Inc.. Retrieved from https://idiyas.com/company/engene

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…